Zacks Research Has Negative Forecast for ESPR Q2 Earnings

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Research analysts at Zacks Research reduced their Q2 2026 EPS estimates for shares of Esperion Therapeutics in a report issued on Tuesday, March 31st. Zacks Research analyst Team now forecasts that the biopharmaceutical company will earn ($0.02) per share for the quarter, down from their prior estimate of ($0.01). The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.29) per share. Zacks Research also issued estimates for Esperion Therapeutics’ Q3 2026 earnings at ($0.02) EPS, FY2026 earnings at ($0.04) EPS, Q3 2027 earnings at ($0.03) EPS, Q4 2027 earnings at $0.08 EPS, FY2027 earnings at $0.21 EPS and Q1 2028 earnings at $0.14 EPS.

Several other analysts also recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Esperion Therapeutics in a report on Thursday, January 22nd. Needham & Company LLC lifted their price objective on Esperion Therapeutics from $4.00 to $5.00 and gave the stock a “buy” rating in a report on Tuesday, March 3rd. HC Wainwright reiterated a “buy” rating on shares of Esperion Therapeutics in a research note on Tuesday, March 10th. Wall Street Zen raised shares of Esperion Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, March 14th. Finally, Citizens Jmp upped their target price on shares of Esperion Therapeutics from $4.00 to $5.00 and gave the stock a “market outperform” rating in a research report on Friday, March 13th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $7.60.

Esperion Therapeutics Trading Down 4.7%

Shares of ESPR stock opened at $2.61 on Thursday. The company has a market cap of $670.27 million, a PE ratio of -15.35, a P/E/G ratio of 1.97 and a beta of 1.17. The company’s fifty day simple moving average is $3.08 and its 200-day simple moving average is $3.16. Esperion Therapeutics has a 52 week low of $0.69 and a 52 week high of $4.18.

Esperion Therapeutics (NASDAQ:ESPR) last released its quarterly earnings data on Tuesday, March 10th. The biopharmaceutical company reported $0.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.23 by ($0.01). The business had revenue of $168.45 million for the quarter, compared to the consensus estimate of $165.12 million.

Institutional Investors Weigh In On Esperion Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of ESPR. R Squared Ltd grew its position in Esperion Therapeutics by 23.5% in the 4th quarter. R Squared Ltd now owns 15,173 shares of the biopharmaceutical company’s stock valued at $56,000 after buying an additional 2,890 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of Esperion Therapeutics by 10.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 38,955 shares of the biopharmaceutical company’s stock worth $144,000 after buying an additional 3,614 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in Esperion Therapeutics by 49.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,617 shares of the biopharmaceutical company’s stock valued at $43,000 after buying an additional 3,822 shares in the last quarter. Eaton Financial Holdings Company LLC boosted its stake in Esperion Therapeutics by 9.4% during the fourth quarter. Eaton Financial Holdings Company LLC now owns 46,595 shares of the biopharmaceutical company’s stock valued at $172,000 after buying an additional 4,000 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC grew its holdings in Esperion Therapeutics by 18.5% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 28,338 shares of the biopharmaceutical company’s stock worth $105,000 after acquiring an additional 4,422 shares during the period. 47.39% of the stock is currently owned by institutional investors.

About Esperion Therapeutics

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.